VasankariVHusuPVåhå-YpyåHet al.Association ofobjectively measured sedentary behaviour and physicalactivity with cardiovascular disease risk. Eur J Prev Cardiol2017; 24: 1311–1318.
2.
HansenDDendalePConinxKet al.The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: a digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol2017; 24: 1017–1031.
3.
MaiorinoMIBellastellaGPetrizzoMet al.Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima-media thickness in type 2 diabetes: follow-up of a randomized trial. Eur J Prev Cardiol2017; 24: 399–408.
4.
PiepoliMFHoesAWAgewallSet al.2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23: NP1–NP96.
5.
BraberTLMosterdAPrakkenNHet al.Occult coronary artery disease in middle-aged sportsmen with a low cardiovascular risk score: the Measuring Athlete’s Risk of Cardiovascular Events (MARC) study. Eur J Prev Cardiol2016; 23: 1677–1684.
6.
JohalSJamsenKMBellJSet al.Do statin users adhere to a healthy diet and lifestyle? The Australian Diabetes, Obesity and Lifestyle Study. Eur J Prev Cardiol2017; 24: 621–627.
7.
SbranaFDal PinoBBigazziFet al.Statin intolerance in heterozygous familial hypercolesterolemia with cardiovasculardisease: after PCSK-9 antibodies what else?Eur J Prev Cardiol2017; 24: 1528–1531.
8.
EllisKLPangJSchultzCJet al.New data on familial hypercholesterolaemia and acute coronary syndromes: the promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur J Prev Cardiol2017; 24: 1200–1205.
9.
EkerstadNPetterssonSAlexanderKet al.Frailty as an instrument for evaluation of elderly patients with non-ST-segment elevation myocardial infarction: a follow-up after more than 5 years. Eur J Prev Cardiol2018; 25: 1813–1821.
10.
ForcadellMJVila-CórcolesAde DiegoCet al.Incidence and mortality of myocardial infarction among Catalonian older adults with and without underlying risk conditions: the CAPAMIS study. Eur J Prev Cardiol2018; 25: 1822–1830.
11.
VigoritoCAbreuAAmbrosettiMet al.Frailty and cardiac rehabilitation: a call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol2017; 24: 577–590.
12.
SchieleFEcarnotFChopardR. Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol2017; 24: 88–100.
13.
MarcassaCPistonoMMaseratiRet al.Disability after cardiac surgery is the major predictor of infections occurring in the rehabilitation phase. Eur J Prev Cardiol2016; 23: 584–592.
14.
SatoTYoshihisaAKannoYet al.Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. Eur J Prev Cardiol2017; 24: 1979–1987.
15.
FresielloLBuysRJacobsSet al.Exercise capacity in left ventricular assist device patients with full and partial support. Eur J Prev Cardiol2016; 24: 168–177.
16.
JenningsCAstinF. A multidisciplinary approach to prevention. Eur J Prev Cardiol2017; 24(3_Suppl.): 77–87.
